Powered by

Axonics® Submits Interim Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System

Jan 02, 2019 - Business Wire

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of  urinary and bowel dysfunction , today announced the submission of interim clinical data from the ARTISAN-SNM pivotal clinical study to the U.S. Food & Drug Administration ("FDA").

The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal cli...